Form 4: Elicio Therapeutics Director Acquires Stock Options

Robert Ruffolo, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.

Summary

• Robert Ruffolo, a director at Elicio Therapeutics, acquired stock options on May 19, 2025.
• The options grant the right to buy 7,900 shares of Elicio Therapeutics' common stock at an exercise price of $5.84 per share.
• The stock options vest fully on the earlier of May 19, 2026, or the next annual meeting of the company's stockholders after the grant date, contingent upon continued service to the issuer.
• Following the transaction, Ruffolo directly owns 7,900 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider confidence can be a positive signal, this is a standard practice.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the transactions of company directors and officers, which can be informative for investors.

Key Dates

Keywords

stock options, Form 4, Elicio Therapeutics, ELTX, director, beneficial ownership, Robert Ruffolo